Margaret A. Cascieri

Overview

Best Publications

• Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

  Mark S. Kramer;Neal Cutler;John Feighner;Ram Shrivastava

  1372
  Citations

• Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor binding

  Gary H. Rasmusson;Glenn F. Reynolds;Nathan G. Steinberg;Edward Walton

  548
  Citations

• Receptor for motilin identified in the human gastrointestinal system.

  Scott D. Feighner;Carina P. Tan;Karen Kulju McKee;Oksana C. Palyha

  513
  Citations

• Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression

  Linda J. Kelly;Pasquale P. Vicario;G. Marie Thompson;Mari R. Candelore

  405
  Citations

• Cloning and Expression of a Novel Neuropeptide Y Receptor

  David H. Weinberg;Dalip J.S. Sirinathsinghji;Carina P. Tan;Lin-Lin Shiao

  361
  Citations

• Molecular cloning and characterization of a new receptor for galanin

  Andrew D Howard;Carina Tan;Lin-Lin Shiao;Oksana C Palyha

  298
  Citations

• Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides

  Linda L Brockunier;Emma R Parmee;Hyun O Ok;Mari R Candelore

  279
  Citations

• Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist

  J. J. Hale;S. G. Mills;M. Maccoss;P. E. Finke

  276
  Citations

• Species differences in prostatic steroid 5 alpha-reductases of rat, dog, and human.

  Tehming Liang;Margaret A. Cascieri;Anne H. Cheung;Glenn F. Reynolds

  276
  Citations

• Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.

  F.D. Tattersall;W. Rycroft;B. Francis;D. Pearce

  249
  Citations

• Amino–aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345

  Tung Ming Fong;Margaret A. Cascieri;Hong Yu;Alka Bansal

  246
  Citations

• Identification, localization and receptor characterization of novel mammalian substance P-like peptides

  Marc M. Kurtz;Ruiping Wang;Michelle K. Clements;Margaret A. Cascieri

  239
  Citations

• Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.

  M A Cascieri;H G Bull;R A Mumford;A A Patchett

  237
  Citations

• The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor.

  M L Bayne;J Applebaum;D Underwood;G G Chicchi

  222
  Citations

• Potent, orally absorbed glucagon receptor antagonists.

  Stephen E. de Laszlo;Candice Hacker;Bing Li;Dooseop Kim

  216
  Citations

• The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor.

  M L Bayne;J Applebaum;G G Chicchi;R E Miller

  207
  Citations

• Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: the modulating effect of cell released IGF binding proteins (IGFBPs).

  R. H. McCusker;C. Camacho‐Hubner;David R Clemmons;M. L. Bayne

  202
  Citations

• Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.

  M. A. Cascieri;E. Ber;Tung Ming Fong;S. Sadowski

  195
  Citations

• Potent and selective human beta(3)-adrenergic receptor antagonists.

  Mari Rios Candelore;Liping Deng;Laurie Tota;Xiao-Ming Guan

  189
  Citations

• Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor.

  Margaret A. Cascieri;Gary G. Chicchi;Joy Applebaum;Nancy S. Hayes

  184
  Citations